Hydroxyurea
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Anemia in Children
Conditions
Sickle Cell Anemia in Children, Sickle Cell Disease
Trial Timeline
Nov 15, 2023 → Sep 1, 2027
NCT ID
NCT05285917About Hydroxyurea
Hydroxyurea is a phase 3 stage product being developed by Novartis for Sickle Cell Anemia in Children. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05285917. Target conditions include Sickle Cell Anemia in Children, Sickle Cell Disease.
What happened to similar drugs?
4 of 20 similar drugs in Sickle Cell Anemia in Children were approved
Approved (4) Terminated (10) Active (7)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05285917 | Phase 3 | Recruiting |
| NCT05853458 | Approved | Terminated |
Competing Products
20 competing products in Sickle Cell Anemia in Children